A critical literature review of health economic evaluations of rotavirus vaccination. Aballea S., Millier A., Quilici S., Carroll S., Petrou S., & Toumi M. 2013.
![A critical literature review of health economic evaluations of rotavirus vaccination [pdf]](https://bibbase.org/img/filetypes/pdf.svg "pdf")
Paper abstract bibtex
Paper abstract bibtex Two licensed vaccines are available to prevent RVGE in infants. A worldwide critical review of economic evaluations of these vaccines was conducted. The objective was to describe differences in methodologies, assumptions and inputs and determine the key factors driving differences in conclusions. 68 economic evaluations were reviewed. RV vaccination was found to be cost-effective in developing countries, while conclusions varied between studies in developed countries. Many studies found that vaccination was likely to be costeffective under some scenarios, such as lower prices scenarios, inclusion of herd protection, and/or adoption of a societal perspective. Other reasons for variability included uncertainty around healthcare visits incidence and lack of consensus on quality of life (QoL) valuation for infants and caregivers. New evidence on the vaccination effectiveness in real-world, new ways of modeling herd protection and assessments of QoL in children could help more precisely define the conditions under which RV vaccination would be cost-effective in developed countries. 2013 Landes Bioscience.
@misc{aballea_s._critical_2013,
title = {A critical literature review of health economic evaluations of rotavirus vaccination},
url = {http://www.landesbioscience.com/journals/vaccines/2012HV0380R1.pdf},
abstract = {Two licensed vaccines are available to prevent RVGE in infants. A worldwide critical review of economic evaluations of these vaccines was conducted. The objective was to describe differences in methodologies, assumptions and inputs and determine the key factors driving differences in conclusions. 68 economic evaluations were reviewed. RV vaccination was found to be cost-effective in developing countries, while conclusions varied between studies in developed countries. Many studies found that vaccination was likely to be costeffective under some scenarios, such as lower prices scenarios, inclusion of herd protection, and/or adoption of a societal perspective. Other reasons for variability included uncertainty around healthcare visits incidence and lack of consensus on quality of life (QoL) valuation for infants and caregivers. New evidence on the vaccination effectiveness in real-world, new ways of modeling herd protection and assessments of QoL in children could help more precisely define the conditions under which RV vaccination would be cost-effective in developed countries. 2013 Landes Bioscience.},
journal = {Human Vaccines and Immunotherapeutics},
author = {{Aballea S.} and {Millier A.} and {Quilici S.} and {Carroll S.} and {Petrou S.} and {Toumi M.}},
year = {2013},
keywords = {*Rotavirus infection/dm [Disease Management], *Rotavirus infection/dt [Drug Therapy], *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *rotavirus gastroenteritis/dm [Disease Management], *rotavirus gastroenteritis/dt [Drug Therapy], *vaccination, *viral gastroenteritis/dm [Disease Management], *viral gastroenteritis/dt [Drug Therapy], Hospitalization, Incidence, adaptive immunity, budget, cost benefit analysis, cost control, cost effectiveness analysis, cost utility analysis, disability adjusted life year, drug cost, drug efficacy, emergency ward, health care cost, health care utilization, hospitalization cost, human, mortality, quality adjusted life year, quality of life, review, seasonal variation, systematic review},
}Downloads: 0
{"_id":"mKhJfGRtqyQ8oiSGx","bibbaseid":"aballeas-milliera-quilicis-carrolls-petrous-toumim-acriticalliteraturereviewofhealtheconomicevaluationsofrotavirusvaccination-2013","author_short":["Aballea S.","Millier A.","Quilici S.","Carroll S.","Petrou S.","Toumi M."],"bibdata":{"bibtype":"misc","type":"misc","title":"A critical literature review of health economic evaluations of rotavirus vaccination","url":"http://www.landesbioscience.com/journals/vaccines/2012HV0380R1.pdf","abstract":"Two licensed vaccines are available to prevent RVGE in infants. A worldwide critical review of economic evaluations of these vaccines was conducted. The objective was to describe differences in methodologies, assumptions and inputs and determine the key factors driving differences in conclusions. 68 economic evaluations were reviewed. RV vaccination was found to be cost-effective in developing countries, while conclusions varied between studies in developed countries. Many studies found that vaccination was likely to be costeffective under some scenarios, such as lower prices scenarios, inclusion of herd protection, and/or adoption of a societal perspective. Other reasons for variability included uncertainty around healthcare visits incidence and lack of consensus on quality of life (QoL) valuation for infants and caregivers. New evidence on the vaccination effectiveness in real-world, new ways of modeling herd protection and assessments of QoL in children could help more precisely define the conditions under which RV vaccination would be cost-effective in developed countries. 2013 Landes Bioscience.","journal":"Human Vaccines and Immunotherapeutics","author":[{"firstnames":[],"propositions":[],"lastnames":["Aballea S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Millier A."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Quilici S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Carroll S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Petrou S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Toumi M."],"suffixes":[]}],"year":"2013","keywords":"*Rotavirus infection/dm [Disease Management], *Rotavirus infection/dt [Drug Therapy], *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *rotavirus gastroenteritis/dm [Disease Management], *rotavirus gastroenteritis/dt [Drug Therapy], *vaccination, *viral gastroenteritis/dm [Disease Management], *viral gastroenteritis/dt [Drug Therapy], Hospitalization, Incidence, adaptive immunity, budget, cost benefit analysis, cost control, cost effectiveness analysis, cost utility analysis, disability adjusted life year, drug cost, drug efficacy, emergency ward, health care cost, health care utilization, hospitalization cost, human, mortality, quality adjusted life year, quality of life, review, seasonal variation, systematic review","bibtex":"@misc{aballea_s._critical_2013,\n\ttitle = {A critical literature review of health economic evaluations of rotavirus vaccination},\n\turl = {http://www.landesbioscience.com/journals/vaccines/2012HV0380R1.pdf},\n\tabstract = {Two licensed vaccines are available to prevent RVGE in infants. A worldwide critical review of economic evaluations of these vaccines was conducted. The objective was to describe differences in methodologies, assumptions and inputs and determine the key factors driving differences in conclusions. 68 economic evaluations were reviewed. RV vaccination was found to be cost-effective in developing countries, while conclusions varied between studies in developed countries. Many studies found that vaccination was likely to be costeffective under some scenarios, such as lower prices scenarios, inclusion of herd protection, and/or adoption of a societal perspective. Other reasons for variability included uncertainty around healthcare visits incidence and lack of consensus on quality of life (QoL) valuation for infants and caregivers. New evidence on the vaccination effectiveness in real-world, new ways of modeling herd protection and assessments of QoL in children could help more precisely define the conditions under which RV vaccination would be cost-effective in developed countries. 2013 Landes Bioscience.},\n\tjournal = {Human Vaccines and Immunotherapeutics},\n\tauthor = {{Aballea S.} and {Millier A.} and {Quilici S.} and {Carroll S.} and {Petrou S.} and {Toumi M.}},\n\tyear = {2013},\n\tkeywords = {*Rotavirus infection/dm [Disease Management], *Rotavirus infection/dt [Drug Therapy], *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *rotavirus gastroenteritis/dm [Disease Management], *rotavirus gastroenteritis/dt [Drug Therapy], *vaccination, *viral gastroenteritis/dm [Disease Management], *viral gastroenteritis/dt [Drug Therapy], Hospitalization, Incidence, adaptive immunity, budget, cost benefit analysis, cost control, cost effectiveness analysis, cost utility analysis, disability adjusted life year, drug cost, drug efficacy, emergency ward, health care cost, health care utilization, hospitalization cost, human, mortality, quality adjusted life year, quality of life, review, seasonal variation, systematic review},\n}\n\n","author_short":["Aballea S.","Millier A.","Quilici S.","Carroll S.","Petrou S.","Toumi M."],"key":"aballea_s._critical_2013","id":"aballea_s._critical_2013","bibbaseid":"aballeas-milliera-quilicis-carrolls-petrous-toumim-acriticalliteraturereviewofhealtheconomicevaluationsofrotavirusvaccination-2013","role":"author","urls":{"Paper":"http://www.landesbioscience.com/journals/vaccines/2012HV0380R1.pdf"},"keyword":["*Rotavirus infection/dm [Disease Management]","*Rotavirus infection/dt [Drug Therapy]","*Rotavirus vaccine/dt [Drug Therapy]","*Rotavirus vaccine/pe [Pharmacoeconomics]","*rotavirus gastroenteritis/dm [Disease Management]","*rotavirus gastroenteritis/dt [Drug Therapy]","*vaccination","*viral gastroenteritis/dm [Disease Management]","*viral gastroenteritis/dt [Drug Therapy]","Hospitalization","Incidence","adaptive immunity","budget","cost benefit analysis","cost control","cost effectiveness analysis","cost utility analysis","disability adjusted life year","drug cost","drug efficacy","emergency ward","health care cost","health care utilization","hospitalization cost","human","mortality","quality adjusted life year","quality of life","review","seasonal variation","systematic review"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"misc","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":["*rotavirus infection/dm [disease management]","*rotavirus infection/dt [drug therapy]","*rotavirus vaccine/dt [drug therapy]","*rotavirus vaccine/pe [pharmacoeconomics]","*rotavirus gastroenteritis/dm [disease management]","*rotavirus gastroenteritis/dt [drug therapy]","*vaccination","*viral gastroenteritis/dm [disease management]","*viral gastroenteritis/dt [drug therapy]","hospitalization","incidence","adaptive immunity","budget","cost benefit analysis","cost control","cost effectiveness analysis","cost utility analysis","disability adjusted life year","drug cost","drug efficacy","emergency ward","health care cost","health care utilization","hospitalization cost","human","mortality","quality adjusted life year","quality of life","review","seasonal variation","systematic review"],"search_terms":["critical","literature","review","health","economic","evaluations","rotavirus","vaccination","aballea s.","millier a.","quilici s.","carroll s.","petrou s.","toumi m."],"title":"A critical literature review of health economic evaluations of rotavirus vaccination","year":2013}